Stocks · News reference
Sanders is calling for tougher AI regulation, including a ban on superintelligent AI, while pushing for greater public oversight.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
In today's rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a comprehensive
The global AI in pharmaceutical market is projected to grow from USD 3.07 billion in 2025 to USD 48.43 billion by 2035, with a CAGR of 31.76%. The U.S. market is expected to reach USD 15.10 billion and Europe USD 12.60 billion by 2035. Growth is driven by generative AI, adaptive trials reducing patient enrollment by 40%, regulatory endorsement including FDA's qualification of AIM-NASH, and increased venture capital investment in AI-first drug discovery platforms.
The S&P 500's Shiller CAPE ratio has reached its highest level since the dot-com bubble peak, driven by unsustainable AI-related earnings gains and massive capital expenditures. While super-intelligent AI could justify current valuations, the market faces significant downside risk. Investors should maintain diversified portfolios rather than betting heavily on either scenario.
CNBC traders picked FTAI Aviation, KLA and Oracle as final trades, while praising NVIDIA’s Hugging Face deal.
Nvidia trades at a reasonable valuation of 25x forward earnings despite projecting 70% growth for next fiscal year, which hasn't been priced into the stock. While the company could potentially double over the next year, the analyst believes this falls short of delivering life-changing returns like the 16x gains seen since early 2023.
Insiders at three major AI companies—Nvidia, Palantir, and Meta—have collectively sold $18.6 billion more stock than they've purchased over the past five years, with insider buying being almost nonexistent. While insider selling can be attributed to tax obligations, the lack of insider buying raises concerns about potential AI bubble risks, as historical patterns show investors often overestimate adoption rates of breakthrough technologies.